title: Tosulfloxacin versus norfloxacin for prevention of infections in chemotherapy-induced neutropenic patients.
abstract: We conducted a non-randomized, prospective study comparing the efficacy of tosulfloxacin with that of norfloxacin in preventing bacterial infection during chemotherapy-induced neutropenic episode. Fifty-one patients with hematological malignancies were included, and a total of 108 episodes of neutropenia were studied. There was no significant difference between the two groups in the incidence of fever, in the time-to-event analysis of febrile episodes nor in the incidence of gram-positive bacteremia despite the broader spectrum of tosulfloxacin. The incidence of gram-negative bacteremia was lower in patients treated with the quinolones as a prophylactic than in the historical controls given polymyxin B. Especially the incidence of bacteremia due to Pseudomonas aeruginosa was significantly less when tosulfloxacin was used. A possible synergistic effect of sulfamethoxazole-trimethoprim in preventing the febrile episode was also observed.
authors.affiliation: Hematology Division, Tokyo Metropolitan Komagome Hospital.
authors.forename: S
authors.initials: S
authors.lastname: Mori
authors.forename: K
authors.initials: K
authors.lastname: Ohashi
authors.forename: H
authors.initials: H
authors.lastname: Akiyama
authors.forename: H
authors.initials: H
authors.lastname: Shoji
authors.forename: H
authors.initials: H
authors.lastname: Sato
authors.forename: S
authors.initials: S
authors.lastname: Tanikawa
authors.forename: H
authors.initials: H
authors.lastname: Sakamaki
authors.forename: Y
authors.initials: Y
authors.lastname: Onozawa
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001424:Bacterial Infections / Q000517:prevention & control*; D004341:Drug Evaluation; D005260:Female; D024841:Fluoroquinolones; D006801:Humans; D008297:Male; D008875:Middle Aged; D009287:Naphthyridines / Q000627:therapeutic use*; D009503:Neutropenia / Q000139:chemically induced* / Q000150:complications; D009643:Norfloxacin / Q000627:therapeutic use*; D011446:Prospective Studies
chemical_list: D000890:Anti-Infective Agents; D000970:Antineoplastic Agents; D024841:Fluoroquinolones; D009287:Naphthyridines; C055185:tosufloxacin; D009643:Norfloxacin